Stanley R. Frankel, M.D., is a member of the Precision BioSciences Board of Directors and Chair of the Science and Technology (S&T) Committee. A 20-year veteran of the industry, Dr. Frankel is a hematologist-oncologist with extensive academic and industry experience in the research, clinical development, and commercialization of immuno-oncology and cellular therapies. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblastic leukemia, multiple myeloma, and lymphoma.
Dr. Frankel was most recently Chief Medical Officer at Cytovia. Previously, he was the Senior Vice President, Cellular Therapy Development at Bristol-Myers Squibb (BMS) where he was responsible for late development portfolio of cellular therapy assets including Breyanzi® and Abecma®. While at BMS, he sat on multiple leadership teams and committees, including the Global Drug Development Leadership Team and the Cell Therapy Commercial Steering Committee. Prior to the BMS acquisition of Celgene, he was Corporate Vice President, Head, Immuno-Oncology & Cellular Therapy, Clinical Research and Development Head, Cell Therapy Clinical Center of Excellence. While at Celgene he co-chaired the Hematology-Oncology Development Committee and served on the Hematology-Oncology Franchise Leadership Team. He served on Joint Steering and/or Joint Development Committees for alliances with JW Therapeutics, Jounce Therapeutics, Astra-Zeneca/Medimmune, Juno Therapeutics, and BeiGene.
Dr. Frankel is a consultant and serves as an independent member of the Board of Directors for Myeloid Therapeutics and a member of Scientific Advisory Boards for Adagene, Immunai, and Sutro Biopharma. Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986. He completed his residency in internal medicine at Mount Sinai Hospital and his fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center where he was Chief Fellow. He has prior academic and clinical appointments at Roswell Park Cancer Institute, Georgetown University, and the University of Maryland prior to joining Columbia University Vagelos College of Physicians and Surgeons as Adjunct Associate Professor of Medicine in the Division of Hematology/Oncology.
What is Stanley Frankel's net worth?
The estimated net worth of Stanley Frankel is at least $171.60 thousand as of December 16th, 2025. Dr. Frankel owns 19,478 shares of Precision BioSciences stock worth more than $171,601 as of July 16th. This net worth approximation does not reflect any other investments that Dr. Frankel may own. Learn More about Stanley Frankel's net worth.
How do I contact Stanley Frankel?
Has Stanley Frankel been buying or selling shares of Precision BioSciences?
Stanley Frankel has not been actively trading shares of Precision BioSciences during the last quarter. Most recently, on Tuesday, December 16th, Stanley Frankel bought 2,700 shares of Precision BioSciences stock. The stock was acquired at an average cost of $4.70 per share, with a total value of $12,690.00. Following the completion of the transaction, the director now directly owns 19,478 shares of the company's stock, valued at $91,546.60. Learn More on Stanley Frankel's trading history.
Who are Precision BioSciences' active insiders?
Are insiders buying or selling shares of Precision BioSciences?
In the last twelve months, Precision BioSciences insiders bought shares 5 times. They purchased a total of 11,181 shares worth more than $53,978.57. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 98,557 shares worth more than $407,257.82. The most recent insider tranaction occured on February, 18th when CEO Michael Amoroso sold 20,559 shares worth more than $78,946.56. Insiders at Precision BioSciences own 2.7% of the company.
Learn More about insider trades at Precision BioSciences. Information on this page was last updated on 2/18/2026.
